ARTL - Artelo Biosciences Inc

https://www.artelobio.com

Momentum: Bearish

Recent News

This Science Applications International Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Monday - Artelo Biosciences ( NASDAQ:ARTL ) , ABM Indus ( NYSE:ABM )

Benzinga • 1 week ago • score: 0.23

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Neutral

Artelo Biosciences Drug Helps Cancer Patients Regain Weight, Eyes Licensing Deal - Artelo Biosciences ( NASDAQ:ARTL )

Benzinga • 1 week, 5 days ago • score: 0.02

ART27.13 patients gained 6.38% weight over 12 weeks vs. 5.42% loss on placebo. Partner talks underway; company eyes licensing instead of self-funding Phase 3. Get a Year of Fast, Actionable Trade Alerts for 60% Off This Labor Day Artelo Biosciences, Inc.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Artelo Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. The company is headquartered in La Jolla, California.

52W High

$28.60

52W Low

$4.20

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

1.46

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

1.22

EV/Revenue (<3 favorable)

N/A

P/S (TTM) (<3 favorable)

N/A

P/B (<3 favorable)

10.84

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

0.34%

Institutions (25–75% balanced)

1.60%

Shares Outstanding

1,321,600

Float

1,317,100

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

Gross Profit (TTM)

EPS (TTM)

-18.93

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-3.57%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Bearish momentum

Value

-1.9137

-1.9796

Trend

Rising

Signal Cross

No cross

As of

Sep. 12, 2025